Taragarestrant

DB21574InvestigationalSmall molecule

Taragarestrant is a small molecule drug. Taragarestrant is under investigation in clinical trial NCT06954961 (A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer).... Taragarestrant has a monoisotopic molecular weight of 474.13 Da.

Mechanism: Pharmacologically active on Estrogen receptor
Curator reviewed
Formula / weight: C₂₅H₂₅Cl₂FN₂O₂ · 475.39 g/mol (avg)
Code names: D-0502

Resolves to

Compound

UNIIKD4HIM135VCAS2118899-51-5ChEMBLCHEMBL5087025ChEBI758604PubChem130330722

Structure

InChIKeyPSJRZBBUWGIUPM-BBNFHIFMSA-NSMILESC[C@@H]1CC2=C(NC3=CC=CC=C23)[C@H](N1CC(C)(C)F)C1=C(Cl)C=C(\C=C\C(O)=O)C=C1Cl

Targets

P03372ESR1

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Taragarestrant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account